Company: TLSA
Filing Date: 2025-06-13
Form Type: 6-K
Source: 0001213900-25-054040
Chunk: 0

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-06-13
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

June 2025

Commission File Number: 001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9 thFloor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive
office)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F☒Form 40-F☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K</div>

On June 13, 2025, Tiziana Life Sciences LTD (the “”)
issued this 6K announcing, that its CEO, Ivor Elrifi, will be giving an oral presentation during the Bio International Convention in Boston,
MA. Mr Elrifi’s presentation will cover the recent clinical findings of Tiziana’s lead drug candidate, intranasal foralumab.
Foralumab is the first fully human anti-CD3 monoclonal antibody administered via the intranasal route. This novel, non-systemic approach
is designed to engage regulatory T cells, promoting immune tolerance while minimizing systemic immune suppression. Immunomodulation by
intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases. Tiziana has
an ongoing Phase 2 trial in non-active Secondary Progressive Multiple Sclerosis and is progressing towards opening a Phase 2 trial in
early Alzheimer’s Disease.

The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth